ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The association between colorectal cancer drugs and heart failure: a real-world pharmacovigilance study of the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a prevalent cancer. Heart failure (HF) is a well-recognized adverse reaction to CRC drugs.
methodsThis study interrogated the FDA Adverse Event Reporting System (FAERS) database from to comprehensively investigate the risk of HF associated with CRC drugs.
resultsThe annual number of reports peaked in 2017 and has shown a consistent upward trend in the most recent period. The physicians constituted the most substantial group. Male patients contributed the most reports. The 65 to 85 age group constituted the majority of the reports. It is notable that the United States was the largest contributor of reports. The majority of HF reports occurred within 0 to 30 days after drug administration. These reports were frequently associated with serious outcomes. There were 20 drugs that met the threshold of not less than 3 reports, including bevacizumab, oxaliplatin, fluorouracil, capecitabine, and cetuximab. The Reporting Odds Ratio (ROR) method, the Proportional Reporting Ratio (PRR) method, the Bayesian Confidence Propagation Neural Network (BCPNN) method, and the Multi-item Gamma Poisson Shrinker (MGPS) method were utilized. Fluorouracil, aflibercept, ramucirumab, atezolizumab, trametinib, and ipilimumab met the criteria of more than 3 reports and a positive ROR signal. A strong association between HF risk and the utilization of aflibercept or ramucirumab in CRC was found.
conclusionThe study offers the first real-world pharmacovigilance analysis of HF risks associated with CRC drugs using the FAERS database. It contributed critical evidence to inform the safe clinical use of CRC drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.